Altimmune/$ALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Altimmune
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Ticker
$ALT
Sector
Primary listing
Employees
57
Headquarters
Website
Altimmune Metrics
BasicAdvanced
$471M
-
-$1.00
0.17
-
Price and volume
Market cap
$471M
Beta
0.17
52-week high
$7.73
52-week low
$2.90
Average daily volume
3.4M
Financial strength
Current ratio
18.55
Quick ratio
18.35
Long term debt to equity
15.246
Total debt to equity
15.246
Interest coverage (TTM)
-57.76%
Profitability
EBITDA (TTM)
-94.374
Gross margin (TTM)
-161,929.27%
Net profit margin (TTM)
-214,860.98%
Operating margin (TTM)
-230,460.98%
Effective tax rate (TTM)
0.77%
Management effectiveness
Return on assets (TTM)
-28.17%
Return on equity (TTM)
-50.57%
Valuation
Price to revenue (TTM)
7,784.946
Price to book
1.78
Price to tangible book (TTM)
1.78
Price to free cash flow (TTM)
-4.722
Free cash flow yield (TTM)
-21.18%
Free cash flow per share (TTM)
-0.767
Growth
Revenue change (TTM)
105.00%
Earnings per share change (TTM)
-25.32%
3-year revenue growth (CAGR)
-15.52%
10-year revenue growth (CAGR)
-37.70%
3-year earnings per share growth (CAGR)
-17.95%
10-year earnings per share growth (CAGR)
-27.94%
What the Analysts think about Altimmune
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Altimmune Financial Performance
Revenues and expenses
Altimmune Earnings Performance
Company profitability
Altimmune News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Altimmune stock?
Altimmune (ALT) has a market cap of $471M as of March 17, 2026.
What is the P/E ratio for Altimmune stock?
The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of March 17, 2026.
Does Altimmune stock pay dividends?
No, Altimmune (ALT) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next Altimmune dividend payment date?
Altimmune (ALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Altimmune?
Altimmune (ALT) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.